about
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.Role of consolidation therapy in transplant eligible multiple myeloma patients.Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agentsPeripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma.Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma.Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo modelSafety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myelomaMaintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myelomaThe timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
P50
Q33409172-D7164FD3-1FD2-4942-B886-1D53C515802BQ38153542-21058ABE-BAA2-46BD-86E3-37B3019C44DFQ38658649-6460EDFB-8811-4B7D-A87F-AC6793B3BF04Q38778519-1AF20C3C-ADA9-4EB1-9FDC-7FC1F1C7EE66Q38832649-F5EB1CD5-9AE0-4BDE-BF0F-7820926931CCQ40404841-A1F53B0B-21CB-4D95-BD96-B6FA9A3D0554Q41666443-DC133A74-AD09-49F3-8541-103855C93700Q42361980-B0706E12-2984-4AF5-A77C-E01DF386A68CQ42979846-FC2ADB84-01D9-4504-ACEE-86134860FCA2Q45961614-9234DA91-FB6B-4C22-AA01-393EFAAFD3EEQ48139344-6D71A301-1CA0-427E-A1E8-89B3A860D7D5Q50934141-CFEBECA7-CE47-4917-B78A-B2B1315155AAQ51812800-284AA320-6990-4209-BAED-424BDF8C7D17Q56364006-C3964C4E-BA6E-47CF-9DFC-C9280617C8F5Q56380305-B17AFCE1-159C-4B0E-9CE7-E78137E90B32Q89900891-92EC6118-0BE0-45A6-87F6-6B5679F87D1DQ91452397-04639B26-F682-45FF-BDA6-AC8516631B9B
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Katia Mancuso
@ast
Katia Mancuso
@en
Katia Mancuso
@es
Katia Mancuso
@nl
Katia Mancuso
@sl
type
label
Katia Mancuso
@ast
Katia Mancuso
@en
Katia Mancuso
@es
Katia Mancuso
@nl
Katia Mancuso
@sl
prefLabel
Katia Mancuso
@ast
Katia Mancuso
@en
Katia Mancuso
@es
Katia Mancuso
@nl
Katia Mancuso
@sl
P106
P21
P31
P496
0000-0002-1169-0129